a key step in tau propagation in the brain in Alzheimer’s disease. They prevent tau from binding to surface receptors by competition. The most effective, VHH H3-2, has a unique binding mode to tau.

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

Lilly cues up filing for amyloid drug donanemab Meanwhile, other developments in Alzheimer's continue apace, with Eli Lilly saying today that it intends to file for approval of amyloid antibody ...

Roche has reported preliminary results on its Alzheimer ... s and Parkinson’s Diseases. The update covered 114 participants who received 1.8 mg/kg or 3.6 mg/kg of the antibody in the double ...

Antibodies taken from alpacas are to be used in a new pandemic flu drug, in a £33 million project led by AstraZeneca.

However, until now, scientists have not investigated whether taking monoclonal antibody therapies could prevent or delay the onset of Alzheimer’s in at-risk individuals. The latest study tackles ...

Data on tau silencing gene therapy VY1706 and anti-tau antibody VY7523 will be presented at the upcoming 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related ...

There are few Alzheimer’s drugs for people with symptoms – and nothing for pre-symptomatic people. The leading drugs are expensive antibody infusions that clear out most of the visible ...